Protein expression of c-erbB-2 and p53 in normal ducts, ductal carcinoma in situ and invasive carcinoma of the same breast. 2006

Marcus Vinicius Martins de Menezes, and Anna Letícia Oliveira Cestari, and Orlando Almeida, and Marcelo Alvarenga, and Glauce Aparecida Pinto, and Maria Salete Costa Gurgel, and Gustavo Antônio de Souza, and Luiz Carlos Zeferino
Centro de Atenção Integral à Saúde da Mulher, Universidade Estadual de Campinas, Rua Alexander Fleming 101, CEP 13083-970 Campinas, São Paulo, Brazil.

OBJECTIVE Breast cancer is thought to derive from progressively aberrant, non-invasive breast lesions, but it is not known exactly how invasive breast cancer develops from these lesions. The aim of this study was to verify the changes in c-erbB-2 and p53 protein expression between non-neoplastic ducts, ductal carcinoma in situ and invasive ductal carcinoma found in the same breast. METHODS This was a cross-sectional study at Centro de Atenção Integral à Saúde da Mulher, Campinas, Brazil. METHODS Fifty-six women with invasive ductal carcinoma and ductal carcinoma in situ in the same breast were included. The expression of c-erbB-2 and p53 proteins was assessed in non-neoplastic and neoplastic cells using immunohistochemical techniques. RESULTS The c-erbB-2 protein was absent in non-neoplastic ducts but was present in 46% and 36% of in situ and invasive carcinoma components, respectively. Only 2% of non-neoplastic ducts, and 18% and 16% of ductal carcinoma in situ and invasive carcinoma components, respectively, were positive for p53 protein. No significant difference in c-erbB-2 and p53 protein expression was observed between in situ and invasive components. The nuclear grade agreement between in situ and invasive carcinoma was very good. CONCLUSIONS The invasiveness of ductal carcinoma in situ seems to be independent of the Her-2/neu and TP53 genes. The general features of an occurrence of breast carcinoma are formulated at the outset of carcinogenesis, and the Her-2/neu and TP53 genes are involved.

UI MeSH Term Description Entries
D006965 Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells. Hyperplasias
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D001940 Breast In humans, one of the paired regions in the anterior portion of the THORAX. The breasts consist of the MAMMARY GLANDS, the SKIN, the MUSCLES, the ADIPOSE TISSUE, and the CONNECTIVE TISSUES. Breasts
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002278 Carcinoma in Situ A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane. Carcinoma, Intraepithelial,Carcinoma, Preinvasive,Intraepithelial Neoplasms,Neoplasms, Intraepithelial,Intraepithelial Carcinoma,Intraepithelial Neoplasm,Neoplasm, Intraepithelial,Preinvasive Carcinoma
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016017 Odds Ratio The ratio of two odds. The exposure-odds ratio for case control data is the ratio of the odds in favor of exposure among cases to the odds in favor of exposure among noncases. The disease-odds ratio for a cohort or cross section is the ratio of the odds in favor of disease among the exposed to the odds in favor of disease among the unexposed. The prevalence-odds ratio refers to an odds ratio derived cross-sectionally from studies of prevalent cases. Cross-Product Ratio,Risk Ratio,Relative Odds,Cross Product Ratio,Cross-Product Ratios,Odds Ratios,Odds, Relative,Ratio, Cross-Product,Ratio, Risk,Ratios, Cross-Product,Ratios, Risk,Risk Ratios

Related Publications

Marcus Vinicius Martins de Menezes, and Anna Letícia Oliveira Cestari, and Orlando Almeida, and Marcelo Alvarenga, and Glauce Aparecida Pinto, and Maria Salete Costa Gurgel, and Gustavo Antônio de Souza, and Luiz Carlos Zeferino
October 2004, European journal of cancer (Oxford, England : 1990),
Marcus Vinicius Martins de Menezes, and Anna Letícia Oliveira Cestari, and Orlando Almeida, and Marcelo Alvarenga, and Glauce Aparecida Pinto, and Maria Salete Costa Gurgel, and Gustavo Antônio de Souza, and Luiz Carlos Zeferino
October 1997, European journal of cancer (Oxford, England : 1990),
Marcus Vinicius Martins de Menezes, and Anna Letícia Oliveira Cestari, and Orlando Almeida, and Marcelo Alvarenga, and Glauce Aparecida Pinto, and Maria Salete Costa Gurgel, and Gustavo Antônio de Souza, and Luiz Carlos Zeferino
May 1993, Human pathology,
Marcus Vinicius Martins de Menezes, and Anna Letícia Oliveira Cestari, and Orlando Almeida, and Marcelo Alvarenga, and Glauce Aparecida Pinto, and Maria Salete Costa Gurgel, and Gustavo Antônio de Souza, and Luiz Carlos Zeferino
August 1995, Japanese journal of clinical oncology,
Marcus Vinicius Martins de Menezes, and Anna Letícia Oliveira Cestari, and Orlando Almeida, and Marcelo Alvarenga, and Glauce Aparecida Pinto, and Maria Salete Costa Gurgel, and Gustavo Antônio de Souza, and Luiz Carlos Zeferino
January 1992, Pathobiology : journal of immunopathology, molecular and cellular biology,
Marcus Vinicius Martins de Menezes, and Anna Letícia Oliveira Cestari, and Orlando Almeida, and Marcelo Alvarenga, and Glauce Aparecida Pinto, and Maria Salete Costa Gurgel, and Gustavo Antônio de Souza, and Luiz Carlos Zeferino
August 1995, International journal of oncology,
Marcus Vinicius Martins de Menezes, and Anna Letícia Oliveira Cestari, and Orlando Almeida, and Marcelo Alvarenga, and Glauce Aparecida Pinto, and Maria Salete Costa Gurgel, and Gustavo Antônio de Souza, and Luiz Carlos Zeferino
July 1990, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
Marcus Vinicius Martins de Menezes, and Anna Letícia Oliveira Cestari, and Orlando Almeida, and Marcelo Alvarenga, and Glauce Aparecida Pinto, and Maria Salete Costa Gurgel, and Gustavo Antônio de Souza, and Luiz Carlos Zeferino
April 1995, Cancer,
Marcus Vinicius Martins de Menezes, and Anna Letícia Oliveira Cestari, and Orlando Almeida, and Marcelo Alvarenga, and Glauce Aparecida Pinto, and Maria Salete Costa Gurgel, and Gustavo Antônio de Souza, and Luiz Carlos Zeferino
October 2014, Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences,
Marcus Vinicius Martins de Menezes, and Anna Letícia Oliveira Cestari, and Orlando Almeida, and Marcelo Alvarenga, and Glauce Aparecida Pinto, and Maria Salete Costa Gurgel, and Gustavo Antônio de Souza, and Luiz Carlos Zeferino
January 2009, Revista da Associacao Medica Brasileira (1992),
Copied contents to your clipboard!